| 查看: 1383 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
高效肺靶向RNA转染，加速肺部RNA药物开发
已经有2人回复
-
二糖的糖脂，合成后sephadex LH-20分离不出来，求助
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有137人回复
-
南方医科大学珠江医院肖计生课题组招收博士生 （2026年入学）
已经有2人回复
-
349药学专硕105500求调剂
已经有0人回复
-
求调剂
已经有1人回复
-
298求调剂一志愿中海洋
已经有3人回复
-
药学调剂申请自荐信，一志愿中南大学
已经有1人回复
-
药学349专硕求调剂
已经有1人回复
-
《左乙拉西坦注射液制备工艺研究、质量控制和稳定性研究》下载
已经有1人回复
» 抢金币啦！回帖就可以得到:
-
讲师身份申请面上项目中标率有影响吗
+1/75
-
青岛科技大学生物工程学院招调剂硕士研究生
+1/71
-
南方油校——资源与环境专硕招生，化学环境生物类专业均可，就业好，有专业壁垒
+1/47
-
招聘︱国家纳米科学中心丁宝全杰青团队诚聘博士后（特别研究助理）
+2/46
-
北京某研究院结构生物学相关专业接收调剂研究生
+1/10
-
三峡大学材化学院能源环保晶态材料课题组接收调剂，招收化学类硕士
+1/10
-
墨子实验室理论计算和模拟研究组诚聘海内外优秀人才
+1/7
-
大连理工大学气体监测与环境催化团队诚聘副教授、助理教授及博士后3-4名
+1/6
-
天津大学利物浦福州联合学院中外合办硕士【首批offer已发出】
+1/5
-
武汉纺织大学全国重点实验室吕永钢教授课题组招收材料、化学、生物相关专业硕士研究生
+1/5
-
半导体光电子器件与集成
+1/4
-
福建师范大学国家级人才团队招收2026年博士研究生
+1/4
-
苏州高校招收08方向调剂
+1/3
-
香港中文大学 生物医学学院/组织工程与再生医学研究所 招聘博士后/研究助理
+1/2
-
2026南京林业大学双一流建设高校——化学工程学院招收化学/材料相关专业硕士生
+1/2
-
福建师范大学环境与资源学院招收2026级硕士生
+1/1
-
一志愿西南交大机械专硕343求调剂
+1/1
-
2026年北京石油化工学院环境学科-水污染控制工程方向课题组欢迎您
+1/1
-
上海交通大学环境智能感知实验室招聘博士后
+1/1
-
广东唯一石化院校——资源与环境专硕招生
+1/1
11楼2015-09-14 11:50:36
7楼2015-08-31 16:02:44
9楼2015-09-01 08:14:29
10楼2015-09-01 08:19:15
